49: Haplotype mismatched myeloablative stem cell transplantation
نویسندگان
چکیده
منابع مشابه
ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety of malignant and non-malignant hematological and congenital diseases. Due to the fact that the human leukocyte antigen system is inherited independently of the blood group system, approximately 40-50% of all HSCTs are performed across the ABO blood group barrier. The expected immune-hematological conseq...
متن کاملNon-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
OBJECTIVE To present an institution's 2-year experience of non-myeloablative allogeneic stem cell transplantation among Chinese patients. DESIGN Retrospective study. SETTING Bone marrow transplantation unit at a university hospital, Hong Kong. PATIENTS Ten patients with multiple myeloma who received non-myeloablative allogeneic stem cell transplantation between March 2000 and October 2002...
متن کاملPrevalence of chimerism after non-myeloablative hematopoietic stem cell transplantation.
CONTEXT AND OBJECTIVE Non-myeloablative hematopoietic stem cell transplantation (NMA-HSCT) is performed in onco-hematological patients who cannot tolerate ablative conditioning because of older age or comorbidities. This approach does not completely eliminate host cells and initially results in mixed chimerism. Long-term persistence of mixed chimerism results in graft rejection and relapse. Inv...
متن کاملPediatric Hematopoietic Stem Cell Transplantation
The introduction and evolution of hematopoietic stem cell transplantation (HSCT) could be traced back to 1950s, to the studies on interactions among irradiation, covering spleen and bone marrow from it and injection of bone marrow cells. Today, HSCT is considered a well-established, effective and promising means of therapy for various malignant and non-malignant medical conditions, both in chil...
متن کاملLoss of mismatched HLA in leukemia after stem-cell transplantation.
BACKGROUND Transplantation of hematopoietic stem cells from partially matched family donors is a promising therapy for patients who have a hematologic cancer and are at high risk for relapse. The donor T-cell infusions associated with such transplantation can promote post-transplantation immune reconstitution and control residual disease. METHODS We identified 43 patients who underwent haploi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2007
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.052